Skip to main content
NCBI home page
Journal of the National Medical Association logoLink to Journal of the National Medical Association
. 2006 Apr;98(4):618–626.

Irbesartan/HCTZ fixed combinations in patients of different racial/ethnic groups with uncontrolled systolic blood pressure on monotherapy.

Elizabeth O Ofili 1, Keith C Ferdinand 1, Elijah Saunders 1, Joel M Neutel 1, George L Bakris 1, William C Cushman 1, James R Sowers 1, Michael A Weber 1
PMCID: PMC2569215  PMID: 16623075

Abstract

The IrbesartaN/hydroChlorothiazide (HCTZ) bLood pressUre reductionS In diVErse patient populations (INCLUSIVE) trial was a multicenter, prospective, open-label, single-arm study evaluating the efficacy and safety of irbesartan/HCTZ fixed combinations in patients > or = 18 years old with uncontrolled systolic blood pressure (SBP, 140-159 mmHg; 130-159 mmHg for type-2 diabetes mellitus patients) after > or = 4 weeks of antihypertensive monotherapy. This analysis focused on different racial/ethnic subgroups. Treatment was sequential: placebo (4-5 weeks), HCTZ 12.5 mg (two weeks), irbesartan/HCTZ 150/12.5 mg (eight weeks) and irbesartan/HCTZ 300/25 mg (eight weeks). Overall, 515 Caucasians, 191 African Americans and 119 Hispanics/Latinos completing placebo treatment were enrolled. Mean SBP changes from baseline (placebo treatment end) to week 18 were -21.5 +/- 13.8 mmHg for Caucasians, -20.7 +/- 16.5 mmHg for African Americans and -22.9 +/- 13.2 mmHg for Hispanics/Latinos, respectively (p<0.001 for each). Mean diastolic BP (DBP) changes were statistically significant (p<0.001) and similar among racial/ethnic subgroups. By week 18, 70% (95% CI, 66%, 74%) of Caucasian, 66% (95% CI, 59%, 74%) of African-American and 65% (95% CI, 57%, 74%) of Hispanic/Latino patients achieved dual SBP/DBP goal. Treatments appeared to be well tolerated. In conclusion, irbesartan/HCTZ treatment provided SBP/DBP goal attainment in approximately two-thirds of Caucasian, African-American and Hispanic/Latino patients with SBP uncontrolled on antihypertensive monotherapy.

Full text

PDF
618

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA. 2002 Dec 18;288(23):2981–2997. doi: 10.1001/jama.288.23.2981. [DOI] [PubMed] [Google Scholar]
  2. Association of Black Cardiologists (ABC) Candesartan Study Group Evaluation of candesartan cilexetil in black patients with systemic hypertension: the ABC Trial. Heart Dis. 2000 Nov-Dec;2(6):392–399. [PubMed] [Google Scholar]
  3. Brown N. J., Ray W. A., Snowden M., Griffin M. R. Black Americans have an increased rate of angiotensin converting enzyme inhibitor-associated angioedema. Clin Pharmacol Ther. 1996 Jul;60(1):8–13. doi: 10.1016/S0009-9236(96)90161-7. [DOI] [PubMed] [Google Scholar]
  4. Chobanian Aram V., Bakris George L., Black Henry R., Cushman William C., Green Lee A., Izzo Joseph L., Jr, Jones Daniel W., Materson Barry J., Oparil Suzanne, Wright Jackson T., Jr Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension. 2003 Dec 1;42(6):1206–1252. doi: 10.1161/01.HYP.0000107251.49515.c2. [DOI] [PubMed] [Google Scholar]
  5. Coca Antonio, Calvo Carlos, Sobrino Javier, Gómez Elisenda, López-Paz José E., Sierra Cristina, Bragulat Ernesto, de la Sierra Alejandro. Once-daily fixed-combination irbesartan 300 mg/ hydrochlorothiazide 25 mg and circadian blood pressure profile in patients with essential hypertension. Clin Ther. 2003 Nov;25(11):2849–2864. doi: 10.1016/s0149-2918(03)80338-7. [DOI] [PubMed] [Google Scholar]
  6. Cooper R., Rotimi C. Hypertension in blacks. Am J Hypertens. 1997 Jul;10(7 Pt 1):804–812. doi: 10.1016/s0895-7061(97)00211-2. [DOI] [PubMed] [Google Scholar]
  7. Cushman W. C., Reda D. J., Perry H. M., Williams D., Abdellatif M., Materson B. J. Regional and racial differences in response to antihypertensive medication use in a randomized controlled trial of men with hypertension in the United States. Department of Veterans Affairs Cooperative Study Group on Antihypertensive Agents. Arch Intern Med. 2000 Mar 27;160(6):825–831. doi: 10.1001/archinte.160.6.825. [DOI] [PubMed] [Google Scholar]
  8. Douglas Janice G., Bakris George L., Epstein Murray, Ferdinand Keith C., Ferrario Carlos, Flack John M., Jamerson Kenneth A., Jones Wendell E., Haywood Julian, Maxey Randall. Management of high blood pressure in African Americans: consensus statement of the Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks. Arch Intern Med. 2003 Mar 10;163(5):525–541. doi: 10.1001/archinte.163.5.525. [DOI] [PubMed] [Google Scholar]
  9. Elliott W. J. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther. 1996 Nov;60(5):582–588. doi: 10.1016/S0009-9236(96)90155-1. [DOI] [PubMed] [Google Scholar]
  10. Fields Larry E., Burt Vicki L., Cutler Jeffery A., Hughes Jeffrey, Roccella Edward J., Sorlie Paul. The burden of adult hypertension in the United States 1999 to 2000: a rising tide. Hypertension. 2004 Aug 23;44(4):398–404. doi: 10.1161/01.HYP.0000142248.54761.56. [DOI] [PubMed] [Google Scholar]
  11. Flack J. M., Saunders E., Gradman A., Kraus W. E., Lester F. M., Pratt J. H., Alderman M., Green S., Vargas R., Espenshade M. Antihypertensive efficacy and safety of losartan alone and in combination with hydrochlorothiazide in adult African Americans with mild to moderate hypertension. Clin Ther. 2001 Aug;23(8):1193–1208. doi: 10.1016/s0149-2918(01)80101-6. [DOI] [PubMed] [Google Scholar]
  12. He Jiang, Muntner Paul, Chen Jing, Roccella Edward J., Streiffer Richard H., Whelton Paul K. Factors associated with hypertension control in the general population of the United States. Arch Intern Med. 2002 May 13;162(9):1051–1058. doi: 10.1001/archinte.162.9.1051. [DOI] [PubMed] [Google Scholar]
  13. Howe P., Phillips P., Saini R., Kassler-Taub K. The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring. Irbesartan Multicenter Study Group. Clin Exp Hypertens. 1999 Nov;21(8):1373–1396. doi: 10.3109/10641969909070855. [DOI] [PubMed] [Google Scholar]
  14. Jamerson K., DeQuattro V. The impact of ethnicity on response to antihypertensive therapy. Am J Med. 1996 Sep 30;101(3A):22S–32S. doi: 10.1016/s0002-9343(96)00265-3. [DOI] [PubMed] [Google Scholar]
  15. Kochar M., Guthrie R., Triscari J., Kassler-Taub K., Reeves R. A. Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension. Am J Hypertens. 1999 Aug;12(8 Pt 1):797–805. doi: 10.1016/s0895-7061(99)00053-9. [DOI] [PubMed] [Google Scholar]
  16. Lewis E. J., Hunsicker L. G., Clarke W. R., Berl T., Pohl M. A., Lewis J. B., Ritz E., Atkins R. C., Rohde R., Raz I. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):851–860. doi: 10.1056/NEJMoa011303. [DOI] [PubMed] [Google Scholar]
  17. McGill J. B., Reilly P. A. Combination treatment with telmisartan and hydrochlorothiazide in black patients with mild to moderate hypertension. Clin Cardiol. 2001 Jan;24(1):66–72. doi: 10.1002/clc.4960240111. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Neutel Joel M., Saunders Elijah, Bakris George L., Cushman William C., Ferdinand Keith C., Ofili Elizabeth O., Sowers James R., Weber Michael A., INCLUSIVE Investigators The efficacy and safety of low- and high-dose fixed combinations of irbesartan/hydrochlorothiazide in patients with uncontrolled systolic blood pressure on monotherapy: the INCLUSIVE trial. J Clin Hypertens (Greenwich) 2005 Oct;7(10):578–586. doi: 10.1111/j.1524-6175.2004.04720.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. O'Brien E, Mee F, Atkins N, Thomas M. Evaluation of three devices for self-measurement of blood pressure according to the revised British Hypertension Society Protocol: the Omron HEM-705CP, Philips HP5332, and Nissei DS-175. Blood Press Monit. 1996 Feb;1(1):55–61. [PubMed] [Google Scholar]
  20. Parving H. H., Lehnert H., Bröchner-Mortensen J., Gomis R., Andersen S., Arner P., Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med. 2001 Sep 20;345(12):870–878. doi: 10.1056/NEJMoa011489. [DOI] [PubMed] [Google Scholar]
  21. Richardson A. D., Piepho R. W. Effect of race on hypertension and antihypertensive therapy. Int J Clin Pharmacol Ther. 2000 Feb;38(2):75–79. doi: 10.5414/cpp38075. [DOI] [PubMed] [Google Scholar]
  22. Rosenstock J., Rossi L., Lin C. S., MacNeil D., Osbakken M. The effects of irbesartan added to hydrochlorothiazide for the treatment of hypertension in patients non-responsive to hydrochlorothiazide alone. J Clin Pharm Ther. 1998 Dec;23(6):433–440. doi: 10.1046/j.1365-2710.1998.00184.x. [DOI] [PubMed] [Google Scholar]
  23. Sasso Ferdinando C., Carbonara Ornella, Persico Marcello, Iafusco Dario, Salvatore Teresa, D'Ambrosio Rosanna, Torella Roberto, Cozzolino Domenico. Irbesartan reduces the albumin excretion rate in microalbuminuric type 2 diabetic patients independently of hypertension: a randomized double-blind placebo-controlled crossover study. Diabetes Care. 2002 Nov;25(11):1909–1913. doi: 10.2337/diacare.25.11.1909. [DOI] [PubMed] [Google Scholar]
  24. Silverstein Russell L., Fenves Andrew Z., Ram C. Venkata S. ARBs and target organ protection. Exploring benefits beyond their antihypertensive effects. Postgrad Med. 2004 Aug;116(2):31-8, 41. doi: 10.3810/pgm.2004.08.1569. [DOI] [PubMed] [Google Scholar]
  25. Toto Robert D., Rinner Steven, Ram C. Venkata S. ACE inhibitors and target organ protection. An expanded role for these antihypertensive agents? Postgrad Med. 2004 Aug;116(2):11-6, 19-22, 48. doi: 10.3810/pgm.2004.08.1567. [DOI] [PubMed] [Google Scholar]
  26. Wang Youfa, Wang Qiong Joanna. The prevalence of prehypertension and hypertension among US adults according to the new joint national committee guidelines: new challenges of the old problem. Arch Intern Med. 2004 Oct 25;164(19):2126–2134. doi: 10.1001/archinte.164.19.2126. [DOI] [PubMed] [Google Scholar]
  27. Weir M. R., Smith D. H., Neutel J. M., Bedigian M. P. Valsartan alone or with a diuretic or ACE inhibitor as treatment for African American hypertensives: relation to salt intake. Am J Hypertens. 2001 Jul;14(7 Pt 1):665–671. doi: 10.1016/s0895-7061(01)01296-1. [DOI] [PubMed] [Google Scholar]

Articles from Journal of the National Medical Association are provided here courtesy of National Medical Association

RESOURCES